Advanced

Randomized trial evaluating the impact of ribavirin mono-therapy and double dosing on viral kinetics, ribavirin pharmacokinetics and anemia in hepatitis C virus genotype 1 infection

Waldenström, Jesper; Westin, Johan; Nyström, Kristina; Christensen, Peer; Dalgard, Olav; Färkkilä, Martti; Lindahl, Karin; Nilsson, Staffan; Norkrans, Gunnar and Krarup, Henrik, et al. (2016) In PLoS One 11(5).
Abstract

In this pilot study (RibaC), 58 hepatitis C virus (HCV) genotype 1 infected treatment-naïve patients were randomized to (i) 2 weeks ribavirin double dosing concomitant with pegylated interferon-α (pegIFN-α), (ii) 4 weeks ribavirin mono-therapy prior to adding pegIFN-α, or (iii) standard-of-care (SOC) ribavirin dosing concurrent with pegIFN-α. Four weeks of ribavirin mono-therapy resulted in a mean 0.46 log10 IU/mL HCV RNA reduction differentially regulated across IL28B genotypes (0.89 vs. 0.21 log10 IU/mL for CC and CT/TT respectively; P = 0.006), increased likelihood of undetectable HCV RNA week 4 after initiating pegIFN-α and thus shortened treatment duration (P

Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
PLoS One
volume
11
issue
5
publisher
Public Library of Science
external identifiers
  • Scopus:84969796323
ISSN
1932-6203
DOI
10.1371/journal.pone.0155142
language
English
LU publication?
yes
id
8f34c092-de60-485e-96e2-70ee0cf965e1
date added to LUP
2016-06-14 12:39:06
date last changed
2016-10-28 11:51:02
@misc{8f34c092-de60-485e-96e2-70ee0cf965e1,
  abstract     = {<p>In this pilot study (RibaC), 58 hepatitis C virus (HCV) genotype 1 infected treatment-naïve patients were randomized to (i) 2 weeks ribavirin double dosing concomitant with pegylated interferon-α (pegIFN-α), (ii) 4 weeks ribavirin mono-therapy prior to adding pegIFN-α, or (iii) standard-of-care (SOC) ribavirin dosing concurrent with pegIFN-α. Four weeks of ribavirin mono-therapy resulted in a mean 0.46 log<sub>10</sub> IU/mL HCV RNA reduction differentially regulated across IL28B genotypes (0.89 vs. 0.21 log<sub>10</sub> IU/mL for CC and CT/TT respectively; P = 0.006), increased likelihood of undetectable HCV RNA week 4 after initiating pegIFN-α and thus shortened treatment duration (P</p>},
  author       = {Waldenström, Jesper and Westin, Johan and Nyström, Kristina and Christensen, Peer and Dalgard, Olav and Färkkilä, Martti and Lindahl, Karin and Nilsson, Staffan and Norkrans, Gunnar and Krarup, Henrik and Norrgren, Hans and Buhl, Mads Rauning and Stenmark, Stephan and Lagging, Martin},
  issn         = {1932-6203},
  language     = {eng},
  number       = {5},
  publisher    = {ARRAY(0xb147088)},
  series       = {PLoS One},
  title        = {Randomized trial evaluating the impact of ribavirin mono-therapy and double dosing on viral kinetics, ribavirin pharmacokinetics and anemia in hepatitis C virus genotype 1 infection},
  url          = {http://dx.doi.org/10.1371/journal.pone.0155142},
  volume       = {11},
  year         = {2016},
}